Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and advanced science to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is also focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey.

Employees

61,975

Sector

Healthcare Facilities & Services

Calendar

2024-12-13 - San Antonio Breast Cancer Symposium

More about the company

Quotes

Date	Price	Change	Volume
24-12-10	234.54 $	-0.62%	657,322
24-12-09	236.00 $	+1.47%	594,321
24-12-06	232.57 $	-0.99%	392,454
24-12-05	234.90 $	-1.05%	466,015
24-12-04	237.39 $	-1.32%	378,829

Delayed Quote Nyse, December 10, 2024 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart LABCORP-HOLDINGS-INC

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

234.54USD

Average target price

261.06USD

Spread / Average Target

+11.31%

Consensus

Profit revisions

estimates-change-chart LABCORP-HOLDINGS-INC

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart LABCORP-HOLDINGS-INC

Company calendar

Market Closed - Nyse Other stock markets 04:00:02 2024-12-10 pm EST			5-day change	1st Jan Change
234.54 ^USD	-0.62%		-2.51%	+3.19%

Nov. 25	Baird Adjusts Price Target on Labcorp to $286 From $289, Keeps Outperform Rating	MT
Nov. 20	Cinven secures Italian nod to sell minority stake in Synlab to Labcorp	RE

Capitalization	19.62B 18.67B 17.3B 15.39B 27.78B 1,665B 30.79B 215B 79.54B 684B 73.65B 72.06B 2,983B	P/E ratio 2024 *	24.9x	P/E ratio 2025 *	18.8x
Enterprise value	24.29B 23.12B 21.42B 19.05B 34.4B 2,061B 38.12B 267B 98.47B 846B 91.18B 89.21B 3,693B	EV / Sales 2024 *	1.87x	EV / Sales 2025 *	1.74x
Free-Float	-	Yield 2024 *	1.24%	Yield 2025 *	1.27%

Baird Adjusts Price Target on Labcorp to $286 From $289, Keeps Outperform Rating	Nov. 25	MT
Cinven secures Italian nod to sell minority stake in Synlab to Labcorp	Nov. 20	RE
Labcorp Holdings Finance Chief Glenn Eisenberg to Retire	Nov. 19	MT
Labcorp Holdings Inc. Announces Executive Changes	Nov. 19	CI
Labcorp Holdings Inc. Announces Chief Financial Officer Changes	Nov. 19	CI
Labcorp Holdings Insider Sold Shares Worth $1,506,836, According to a Recent SEC Filing	Nov. 13	MT
HSBC Upgrades Labcorp to Buy, Price Target is $270	Oct. 30	MT
Piper Sandler Adjusts Price Target on Labcorp Holdings to $240 From $235, Maintains Neutral	Oct. 28	MT
Deutsche Bank Adjusts Price Target on Labcorp to $231 From $230	Oct. 25	MT
UBS Raises Price Target on Labcorp to $293 From $270, Maintains Buy Rating	Oct. 25	MT
Baird Adjusts Price Target on Labcorp to $289 From $282, Maintains Outperform Rating	Oct. 25	MT
Barclays Adjusts Price Target on Labcorp to $249 From $234, Maintains Equalweight Rating	Oct. 25	MT
Leerink Partners Adjusts Price Target on Labcorp to $268 From $259, Maintains Outperform Rating	Oct. 25	MT

Baird Adjusts Price Target on Labcorp to $286 From $289, Keeps Outperform Rating	Nov. 25	MT
HSBC Upgrades Labcorp to Buy, Price Target is $270	Oct. 30	MT
Piper Sandler Adjusts Price Target on Labcorp Holdings to $240 From $235, Maintains Neutral	Oct. 28	MT
Deutsche Bank Adjusts Price Target on Labcorp to $231 From $230	Oct. 25	MT
UBS Raises Price Target on Labcorp to $293 From $270, Maintains Buy Rating	Oct. 25	MT

Labcorp Holdings Inc. Stock

Equities

LH

US5049221055

Healthcare Facilities & Services

Valuation: Labcorp Holdings Inc.

Chart: Labcorp Holdings Inc.

Latest news: Labcorp Holdings Inc.

Last Transcript: Labcorp Holdings Inc.

Analysts' recommendations: Labcorp Holdings Inc.

Press Releases: Labcorp Holdings Inc.

News in other languages: Labcorp Holdings Inc.

Quotes and Performance

Course Extremes

ETFs: Labcorp Holdings Inc.

Other Healthcare Facilities & Services

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Labcorp : Acquires Select Assets of Lab Works	Nov. 20	PU
Labcorp : CFO Glenn Eisenberg Announces Plans to Retire Form 8 K	Nov. 19	PU
Labcorp : Launches New Global Trial Connect Enhancements to Streamline Site Workflow	Nov. 12	PU
Praia Health Secures Strategic Investment from Labcorp Venture Fund, Announces New Collaboration to Streamline Patient Lab Ordering Experience	Nov. 04	BU
Labcorp : Announces Availability of First Companion Diagnostic Assay to Identify Gastric Cancer Patients Eligible for Targeted Treatment with VYLOY™	Oct. 31	PU

Cinven verringert Synlab-Beteiligung - Labcorp steigt ein	Sep. 17
MORNING BRIEFING - USA/Asien	23-03-17
Usa : obbligo vaccinale Biden mette alla prova fornitura test	21-09-13
Warnungen vor Aufhebung der englischen Corona-Maßnahmen nehmen zu	21-06-07
Roche : erhält FDA-Notfallzulassung für Sars-CoV-2-Antikörpertest	20-12-01

1 day	-0.62%
1 week	-2.51%
Current month	-2.75%
1 month	-3.24%
3 months	+6.45%
6 months	+19.71%
Current year	+3.19%

Name	Weight	AuM	1st Jan change	Investor Rating
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	1.97%	2 M€	-.--%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.95%	7 M€	+12.54%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
LABCORP HOLDINGS INC.	-0.62%	-2.51%	+8.28%	-18.67%	19.62B
HCA HEALTHCARE, INC.	-0.54%	-3.14%	+23.01%	+30.07%	80.24B
CVS HEALTH CORPORATION	-1.64%	-6.83%	-26.56%	-44.21%	69.4B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.86%	+7.73%	+11.41%	+88.79%	28.06B
NATERA, INC.	-0.80%	-1.61%	+186.24%	+86.16%	21.97B
FRESENIUS SE & CO. KGAA	+1.76%	+1.38%	+22.02%	+1.67%	20.05B
QUEST DIAGNOSTICS INCORPORATED	+0.16%	-2.15%	+16.59%	-1.00%	17.69B
FRESENIUS MEDICAL CARE AG	-0.04%	+1.47%	+18.30%	-16.47%	14.02B
TENET HEALTHCARE CORPORATION	-1.35%	-1.54%	+94.41%	+83.41%	13.23B
DAVITA INC.	-2.69%	-6.22%	+42.97%	+45.36%	12.61B
Average	-0.39%	-1.16%	+39.67%	+25.51%	29.69B
Weighted average by Cap.	-0.50%	-2.15%	+24.79%	+16.25%

	2024 *	2025 *
Net sales	12.98B 12.35B 11.45B 10.18B 18.38B 1,101B 20.37B 143B 52.62B 452B 48.72B 47.67B 1,973B	13.76B 13.1B 12.14B 10.8B 19.49B 1,168B 21.6B 151B 55.8B 480B 51.67B 50.55B 2,093B
Net income	887M 844M 782M 696M 1.26B 75.28B 1.39B 9.74B 3.6B 30.91B 3.33B 3.26B 135B	1.03B 985M 913M 812M 1.47B 87.8B 1.62B 11.36B 4.19B 36.05B 3.88B 3.8B 157B
Net Debt	4.67B 4.45B 4.12B 3.66B 6.61B 396B 7.33B 51.29B 18.94B 163B 17.53B 17.16B 710B	4.32B 4.11B 3.81B 3.39B 6.12B 367B 6.79B 47.48B 17.53B 151B 16.23B 15.88B 657B